Short Interest in Check-Cap Ltd. (NASDAQ:CHEK) Declines By 59.2%

Check-Cap Ltd. (NASDAQ:CHEK) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 473,700 shares, a decline of 59.2% from the September 15th total of 1,160,000 shares. Approximately 9.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,890,000 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 2,890,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 9.0% of the shares of the stock are sold short.

Check-Cap Stock Performance

Shares of NASDAQ:CHEK opened at $1.82 on Monday. Check-Cap has a 52-week low of $0.56 and a 52-week high of $3.13. The company has a fifty day moving average of $1.42 and a 200-day moving average of $1.00. The company has a market capitalization of $10.65 million, a PE ratio of -0.61 and a beta of 0.50.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Check-Cap in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.